23 After the first 6 months, therefore, there are three scenarios: The Villalta score at both the 3-month and 6-month follow-up visit is ≤4, in which case the patient is advised to discontinue ECS therapy.
For the remaining one, no marginal bone loss had been observed up to 24 months of functional loading, but an average level of marginal bone loss (2.74 mm) was observed in 40 months; therefore, it is under maintenance treatment.
The study of Khandelwal treated exclusively patients with poor glycemic control (HbA1c 7.5–11.4 %) and had 98 % implant survival, after 4 months; therefore, he concluded that implant therapy is successful even in poorly controlled diabetes [19].
As stated earlier, the connection for Specimen No. 2 had failed after 4½ months; therefore, it is anticipated that better performance, likely similar to Specimen No. 1, may have been observed if a failure of the connection had not occurred.
However, the effect of adjunctive therapy diminishes with time, being the most positive effect is within 1 to 2 months; therefore, the risk for reinfection favors repeated SRD application in peri-implant areas, meaning that this anti-infective/anti-inflammatory must be periodically repeated (Renvert et al. 2006; Bassetti et al. 2014; Salvi et al. 2007; Bonito et al. 2005).
The loss of the V-ATPase a3 subunit results in early mortality (∼3 weeks after birth) compared to the clcn7 mutants that survive for 2 3 months; therefore, the a3 mutant mice may not survive long enough to develop retinal degeneration.
However, as mentioned earlier 94% the general population was immunized in 2002 against MenC and the current coverage in the NIP is approximately 95% at 14 months, therefore little differences may be expected.
mo = months *Data collected at 6 months, therefore actual duration would be longer.
The patients lost to follow-up after the visit at 2 months therefore were not dissatisfied patients.
